# Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

> **NCT05875948** · PHASE2 · UNKNOWN · sponsor: **River 2 Renal Corp.** · enrollment: 95 (estimated)

## Conditions studied

- Hepatorenal Syndrome
- Acute Kidney Injury

## Interventions

- **DRUG:** R2R01
- **DRUG:** Terlipressin

## Key facts

- **NCT ID:** NCT05875948
- **Lead sponsor:** River 2 Renal Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-30
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2023-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05875948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05875948, "Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05875948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*